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METHODS
The first Valve Academic Research Consortium (VARC) con-
sensus manuscript was published in 2011, with an update in 
2012.(3) This standardised the definitions of many factors 
pertaining to TAVI, and was used here where relevant. 
The heart team
All cases were done in the 2 private hospitals. Collaboration 
was, however, set up between the 2 hospitals to ensure expo-
sure to more cases. Each hospital nominated a cardiologist, a 
cardiothoracic surgeon and an anesthesiologist, and we en-
deavoured to have team members from both hospitals present 
at all heart team discussions and implants. The team at Mediclinic 
Panorama nominated a cardiologist from an academic hospital 
(H.W.) to expand exposure to the state sector and improve 






The first transcatheter aortic valve implantation (TAVI) was 
performed in 2002(1) and was followed by rapid expansion of 
the technology and utility of this procedure. The first implants 
were done in South Africa in 2009.(2) The local use of TAVI 
has been hampered by low patient numbers. In an attempt to 
optimise our experience, we established a public–private part-
nership between 2 busy private hospitals in the Mediclinic 
group (Panorama and Vergelegen) and the Division of Cardi-
ology at Stellenbosch University and Tygerberg Hospital. We 
collected data for all patients prospectively and reported on 
our initial short-term experience of 79 patients in 2012.(2) In 
November 2014, the national South African Heart Registry on 
TAVI (SHARE-TAVI registry) was initiated and has as its goal to 
include all TAVI cases performed in the country. Our data were 
collected in parallel to the SHARE-TAVI registry, and this report 
is on our first 244 patients, most of whom were not part of the 
SHARE-TAVI registry. A major obstacle to the wider utility of 
TAVI is the high cost of the device and funder reluctance to 
provide funding. A paucity of local data adds to this reluctance. 
The aim of the study was to describe our procedural and 
follow-up data. 
Introduction: We describe the largest South African 
transcatheter aortic valve implantation (TAVI) outcome 
report of a single team in the Western Cape, over a 
7-year period from 2009 - 2016.
Methods: All patients who received TAVI at Mediclinic 
Vergelegen and Mediclinic Panorama were prospectively 
entered into a database. A total of 244 implants (61 
CoreValve and 183 Edwards valves) were performed.
Results: Patients were high risk with a mean STS score 
of 7.89 (standard deviation (SD) 5.7) and mean logistic 
EuroSCORE of 26.5 (SD 12.5). There was a trend toward 
lower risk over time. Procedures were initially per-
formed mainly via a transapical approach, but this 
changed to mostly transfemoral with the introduction 
of smaller delivery systems. Procedural success rate 
was 91.8% for CoreValve and 88.5% for Edwards cases. 
Mean length of hospital stay following TAVI was 9 days 
initially, but this declined to 4 days for the latter part of 
our experience. One year mortality was 19% and one 
year stroke rate was 10%.
Conclusion: Despite the limitations of a study of this 
nature, our group could document outcomes similar to 
international studies, with improvements over time and 
illustrating successful cooperation between different 
hospitals to expand exposure and experience in a 
resource-constrained environment.   
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 ■ clinically detectable cerebrovascular accidents (CVA) at 
1 year; 
 ■ New York Heart Association (NYHA) dyspnoea grading 
at 1 year. 
RESULTS
Patient population
A total of 244 patients were entered between October 2009 
and September 2016. Until July 2011, all implants were Edwards 
valves. Thereafter we used both the  Medtronic CoreValve and 
Edwards valves. A total of 61 CoreValves and 183 Edwards 
valves were implanted. 
Patient risk profi le 
The patient cohort had a male preponderance, with 55.7% 
males. Most of the patients were octogenarians, with an 
average age of 80 (range 50 - 94). Our cohort had a mean 
STS-score predicted mortality of 7.89% (SD 5.7) and a mean 
logistic EuroSCORE of 26.5% (SD12.5). A decrease in the STS 
score was observed in the latter phases of the study period. 
The same decrease in Log EuroSCORE was not observed 
(Figure 1). Mean age did not change over time. Factors not 
well accounted for by the STS score, such as porcelain aorta 
and frailty, were often present in our patients. Table I illustrates 
the proportions of patients who had significant associated 
comorbidities. 
Patient population 
The study received ethical approval from the University of 
Stellenbosch’s ethics committee (N16/01/005). All patients 
who received a TAVI at the 2 participating hospitals (Mediclinic 
Panorama and Mediclinic Vergelegen) were entered into a 
database. This database was managed by the lead author and 
was separate to the SHARE-TAVI registry. 
Patient risk evaluation
At the start of the study, the logistic EuroSCORE and Society of 
Thoracic Surgeons Score (STS – score) predicted risk of mor-
tality score and were documented for all patients. Although the 
EuroSCORE was later updated to the EuroSCORE II, we con-
tinued to document the logistic EuroSCORE for continuity.
Imaging
All patients received detailed preprocedural transthoracic 
echocardiograms (TTE). Parameters documented included left 
ventricular ejection fraction (LVEF) (measured either with 
Simpson’s or the Teicholtz method), mean gradient over aortic 
valve, and aortic valve area (AVA) (measured by the conti-
nuity equation and planimetry). Paravalvular aortic regurgitation 
(AR) was evaluated by a combination of aortography (Sellers 
method(4)), transoesophageal echo (TOE) (according to 
VARC-2 definitions(3)), and end-diastolic pressure gradient over 
the valve. 
Procedures
The procedures were performed over an extended period and 
evolved with growing experience. All procedures were per-
formed in a cathlab under general anaesthesia, with TOE 
guidance. Access was gained via various routes: femoral arteries, 
transapical puncture with surgical preclosure of the apex, 
transaortic with a mini-sternotomy, or axillary artery cutdown. 
The programme was initiated with the Edwards SAPIENTM 
system (Edwards LifesciencesTM, Irvine, California) and later the 
Edwards SAPIEN XT and CoreValve (Medtronic, IL). This study 
did not include any cases of Edwards SAPIEN3 or Medtronic 
Evolut R valves. Procedural success was defined as per VARC-2 
: Absence of procedural mortality and correct positioning of a 
single prosthetic heart valve into the proper anatomical location 
and intended performance of the prosthetic heart valve (no 
prosthesis–patient mismatch and mean aortic valve gradient 
20mmHg or peak velocity 3m/s, and no moderate or severe 
prosthetic valve regurgitation).(3) 
Outcomes
Outcomes documented at 1 year included: 
 ■ 1-year survival (mortality data were subdivided into 
procedural mortality [up to 72 hours post procedure], 
mortality before discharge from hospital, and mortality in 
first year after TAVI); 
FIGURE 1: Preprocedural risk prediction scores for 
patients undergoing Edwards Sapien TAVI procedures 
in the fi rst to last quarter of the cohort. The cohort was 
divided into quarters and average risk scores were calculated 
for each group.
Predicted mortality
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8FIGURE 3: Mean Length of hospital stay over reporting 
period. The cohort was divided into quarters, and mean 
duration of hospital stay was calculated for each of the groups. 
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approach (75%, 14%, and 11% respectively). Initially, the only 
device available was the Edwards Sapien valve, which required 
a 22-24French sheath for femoral access. This made femoral 
access impossible in most of the initial cases, and, therefore, a 
large number were done via transapical access – see Figure 2. 
Patients underwent general anaesthesia to facilitate continuous 
TOE guidance in all cases. Mean procedure time was 83min 
(SD 30.8) and mean screening time 16min (SD 8.9). Procedural 
success was achieved in 91.8% of CoreValve cases and 88.5% 
Preprocedural imaging fi ndings
Most patients had preserved left ventricular systolic function 
with a mean LVEF of 54% (range: 15 - 78%; SD=13%). Very few 
patients with extremely low LVEF were included, as we viewed 
an LVEF below 20% without proof of contractile reserve as a 
contra-indication to TAVI, in line with exclusion criteria of 
earlier trials. Mean transaortic gradient was 46mmHg (SD 
15.6mmHg) and mean aortic valve area 0.7cm2 (SD 0.16cm2). 
Coronary artery disease was common, but revascularisation 
was only considered in symptomatic patients or life threat-
ening cases. A detailed evaluation of this will be the focus of a 
separate study. Preprocedural valve sizing was done with a 
combination of TOE and computerised tomography (CT) 
scanning. As the reliability of the CT scans improved, this 
became our preferred mode. Peripheral access vessels were 
evaluated with either an aortogram at the time of coronary 
angiography or a CT scan. The major benefit of CT is evaluation 
and location of calcifications, and after a number of unforeseen 
vascular problems in patients who did not receive CT evaluation, 
we adopted CT as the method of choice.
Procedural data
An average of 2.7 procedures was performed per dedicated 
theatre day. Apart from a single trans-axillary CoreValve 
implant, 3 different approaches to vascular access were used, 
depending on the extent of the ileofemoral and aortic root 
calcification determined from pre-procedural assessment. The 
transfemoral approach was generally favoured if amenable, 
followed by the transapical approach and the transaortic 
7-YEAR EXPERIENCE OF TAVI
TABLE I: Preprocedural comorbidities.
Previous coronary artery bypass graft surgery 38.9% (95/244)
Previous surgical aortic valve replacement 2.04% (5/244)
Preprocedural pacemakers 16.8% (41/244)
Documented frailty 4.09% (10/244)
Preprocedural major organ system dysfunction# 49.5% (121/244)
Underlying/previously diagnosed malignancy 
(active/current)
9.83% (24/244)
Class 3 obesity (BMI >35kg/m2) 10.24% (25/244)
Porcelain aorta 9% (22/244)
Previous stroke/peripheral vascular disease 13.93% (34/244)
Preprocedural atrial fi brillation 15.16% (37/244)
Creatinine (umol/liter) Median (SD)  114(75)
Ejection fraction (%) Median (SD)  53(13)
# Defined as LVEF <45% and/or eGFR <60ml/min/1.73m2 and/or documented 
respiratory failure in preprocedural notes.
FIGURE 2: TAVI vascular access approach for the 183 
Edwards valves only. Each third consisted of 61 cases. 
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of Edwards cases (mean for entire cohort 89.3%). This lower 
than expected number was mostly driven by moderate post-
procedural AR accounting for approximately 9% of the 10.7% 
of patients, where procedural success was not attained. Mean 
length of hospital stay following TAVI was: Intensive care unit 
(ICU) – 2.19 days (SD 2.58), high care – 2.2 days (SD 2.14), and 
general ward – 3.36 days (SD 2.66). Hospital stay tended to 
become shorter with experience – see Figure 3. 
Major outcomes  
1-year survival 
Mortality data were available for 219 of the 244 patients at 1 
year following TAVI. Most of the missing patients were referred 
from far away and we could not obtain follow-up data despite 
significant efforts. 81% of patients were alive at 1 year (19% 
all cause 1-year mortality). Of the 46 patients that died in the 
first year, the breakdown was as follows: 9 (19.5% of total 
mortality) procedural, 6 (13% of total mortality) prior to dis-
charge from hospital, and the remaining 31 deaths (67.3%) 
during the 1-year follow up. (See Figure 4).  
Causes of the 9 procedural deaths were:
1. Myocardial infarction (left main stem obstruction).
2. Aortic tear.
3. Aortic tear.
4. Ventricular tachycardia, failed resuscitation.
5. Ruptured abdominal aortic aneurysm.
6. Unexplained (day 2 postprocedural).
7. Left ventricular perforation.
8. Severe AR post deployment.
9. Right ventricular perforation by pacemaker wire.
The causes of death in the 6 patients who died in hospital 







One-year mortality tended to improve with experience: for 
Edwards valves, the first 50 cases had 17% 1-year mortality vs. 
8% for the last 50 (p = 0.35). For CoreValve cases, it improved 
from 34% - 13% from the first 30 to the last 30 cases (p=0.07) 
(see Figure 5).
Cerebrovascular accidents (CVA) 
The 1-year incidence of clinically detected CVAs was 10%. 
Eight (33%) occurred in the first 72 hours following the 
procedure, and the remaining 16 (66%) occurred during the 
FIGURE 4: Timing of mortality in the fi rst year 
following the procedure (n=46).
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FIGURE 5: Mortality rates for the fi rst parts and last 
parts of each of the valve types – demonstrating a signifi -
cant improvement in 1-year survival with technological 
































first year follow-up. Of those occurring in the inpatient period, 
2 events were fatal. It is important to note that, preprocedural, 
the cohort had a 14% incidence of prior documented CVA or 
severe peripheral vascular disease – indicating the overall 
vascular risk of this advanced age group.
New York Heart Association (NYHA) dyspnoea grading
The pre-and postprocedural NYHA dyspnoea ratings are 
illustrated in Figure 6.
Secondary outcomes
Echocardiographic parameters pre-and postprocedural are 
compared in Figure 7. There was a significant decrease in mean 
gradient over the valve (46mmHg - 10mmHg), accompanied 
by a rise in valve area (AVA) from 0.7cm2 - 1.6cm2.
Complications
Complications are documented in Table II and are all according 
to VARC-2 criteria. The results exclude 5 cases of elective 
TAVI in surgical bioprosthesis implants. The 5 TAVI- in -TAVI 
cases listed in Table II are cases where the first TAVI implant 
was incorrect and required a second valve to be implanted. 
Since vascular complications are major contributors to mor-
bidity and mortality in TAVI, we evaluated the difference in 
this complication according to the device used (see Table III). 
Our initial experience was exclusively with very large bore 
(22-24French) Edwards SAPIEN femoral and transapical 
devices. Minor vascular complications came down from 17% to 
10% with the introduction of the (18-20French) e-Sheath of 
the SAPIEN XT valves. Major vascular complications were 
frequent with the transapical approach (which was often used 
in our early experience), and less so with the switch to the 
transaortic approach, although absolute numbers are low.
DISCUSSION
The TAVI landscape in South Africa differs vastly from Europe 
and the US where most data are generated. In Europe, the 
average number of TAVI centres is almost one per million of 
population and the average number of implants per centre is 
41/yr.(5) We have only 11 centres performing TAVI and the 
local guidelines state that a team should aim to perform more 
than 10/yr.(6) In 2015 and 2016 only 5 of the teams reached 
this target (data presented at SA Heart® Congress 2016 based 
on SHARE TAVI registry). This can probably be explained 
partially by our smaller elderly population, but another large 
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TABLE II: VARC-2 defined procedural complications.
Complication Incidence 
Life threatening bleeding 11/244 (4.51%)
Major bleeding 2/244 (0.82%)
Minor bleeding 1/244 (0.41%)
Major vascular injury 14/244 (5.74%)
Minor vascular injury 17/244 (6.97%)
Permanent pacemaker placement 12/244 (4.92%)
Stroke/TIA 6/244 (2.46%)
TAVI - in - TAVI 5/244 (2%)
FIGURE 6: Preprocedural and 1-year NYHA dyspnoea 
grading. 
Dyspnoea ratings
NYHA 1 NYHA 2 NYHA 3 NYHA 4
























FIGURE 7: Echocardiographic aortic valve parameters 
pre- and post-intervention.
Echocardiographic parameters
Preprocedural 30 days postprocedural












































contributor is resistance to funding the procedure. Funders 
claim that inadequate data exist pertaining to the outcomes of 
local patients. Our study documents local experience over an 
extended period, which embraced the evolution of the 
techniques and technology.
In line with trends elsewhere, our patient population was 
elderly and risk scores used changed over time. The mean STS 
scores ranged from high risk (>6%) initially to intermediate risk 
(5.5%) for the last quartile of our study population. This is in 
line with the cautious evolution of entry criteria for randomised 
studies. In the randomised Placement of Aortic Transcatheter 
Valves (PARTNER) trial, the average STS score was 11.6%(7) 
and in PARTNER 2 it was 5.8%.(8) It is not clear why the mean 
log EuroSCORE did not evolve in the same way, but the 
simplicity of this scoring system possibly omitted certain signi-
ficant risk factors. This, together with the mean age remaining at 
more than 80 years, however confirms the cautious approach 
to patient selection used by the team.
Extensive echocardiographic parameters were documented 
both pre- and postprocedurally, but these were performed by 
many operators in different hospitals and were not verified by 
a core laboratory. We therefore elected to only report on the 
hard parameters like valve area and gradient. Paravalvular aortic 
regurgitation is the most obvious omission, as this is linked to 
poor outcomes – but is also extremely difficult to reliably 
quantify. 
Procedures were performed under general anaesthesia to 
enable TOE guidance, in contrast to many first world centres 
opting to use conscious sedation and to forego TOE for TTE. 
The obvious benefits of TOE include immediate diagnosis of 
complications, additional information on valve sizing, and 
evaluation of procedural success. Our team only adopted a 
routine sedation policy once we felt comfortable with our 
ability to function without the benefits of TOE. This experience 
is not reported here, but we did observe significant improve-
ments in postprocedural recovery times.
Previously reported 1-year all-cause mortality rates in landmark 
trials/registries were 24% (PARTNER A),(7) 24% (SOURCE),(9) 
14% (CoreValve US Pivotal),(10) 12% (PARTNER 2A)(8) and 
21.5% in the Brazilian Registry.(11) Our 1-year mortality data 
improved significantly over time with an 8% and 13% 1-year 
mortality rate for the last cohorts of both Edwards and 
CoreValve patients respectively. This emphasises the learning 
curve for TAVI – as well as improvements in equipment. 
Experience was also reflected in hospital stay, but not in vas-
cular and bleeding complications. Procedural success was 
relatively low, but this can largely be explained by our strict 
adherence to the paravalvular AR criterion of moderate or 
more as being indicative of failure.
The relatively high stroke rate needs clarification. Newer studies 
looking at strokes after TAVI require a formal neurological 
evaluation (using a reproducible scoring system) pre- and post-
procedure. Our documentation of this outcome was probably 
not on the same standard, and many of the patients were 
referred back to other centres. The exact nature of some of 
these events was therefore not verified. Over time, the team 
tended to be more aggressive with anti-thrombotic treatment 
and the omission of balloon predilatation used in the latest 
Medtronic Evolut R valves may lead to better results in future.
Vascular complications are low compared to other studies.(12,13) 
An analysis of the trend in this complication over our study 
period is however difficult to show, because of changes in mul-
tiple variables: We initially performed open surgical exposure of 
the femoral artery, but with time chose to use percutaneous 













Transfemoral Edwards Sapien (n=50) 3 (6%) 1 (2%) 1 (2%) 4 (8%) 6 (12%)
Transfemoral Edwards Sapien XT (n=84) 3 (3.57%) 0 (0%) 0 (0%) 5 (5.95%) 7 (8.33%)
Transaortic Edwards Sapien (n=18) 2 (11.11%) 0 (0%) 0 (0%) 2 (11.11%) 0 (0%)
Transapical Edwards Sapien (n=31) 3 (9.68%) 1 (3.23%) 0 (0%) 3 (9.68%) 0 (0%)
Medtronic CoreValve (n=61) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 4 (6.56%)
11 (4.51%) 2 (0.82%) 1 (0.41%) 14 (5.74%) 17 (6.97%)
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closure devices such as ProStar (Abbott, IL), and later Proglide 
(Abbott, IL). Using ultrasound guidance to locate the femoral 
artery has been used more recently, and seems likely to reduce 
complications further. A further explanation for the relatively 
low initial major vascular complications for the femoral ap-
proach is that almost half of the cases were performed via non-
femoral access, and only patients with very good femoral 
anatomy were considered for this approach.
CONCLUSION
Despite the limitations of a study of this nature, our group 
could document outcomes similar to international studies – 
with improvements over time and illustrating successful co-
operation between different hospitals to expand exposure and 
experience in a resource-constrained environment.
LIMITATIONS 
The research is subjected to the limitations of a retrospective 
reporting of data. Comparison between the 2 different valve 
types should not be made as the 2 programmes were started 
at different times in our experience curve. A more detailed 
analysis of echocardiographic parameters would have been 
valuable, but the collection of this data was not uniform enough. 
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